Regulatory Actions of Toll-Like Receptor 2 (TLR2) and TLR4 in Leishmania donovani infection in the liver

Infection and Immunity

Volumn 81, Issue 7, 2013, Pages 2318-2326

  Murray, Henry W ^a   Zhang, Yunhua ^a   Zhang, Yan ^a   Raman, Vanitha S ^b   Reed, Steven G ^b   Ma, Xiaojing ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b Infectious Diseases Research Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; MESSENGER RNA; STIBOGLUCONATE SODIUM; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHEMOTHERAPY; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; GRANULOMA; HEPATITIS; LEISHMANIA DONOVANI; LEISHMANIASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ANIMALS; ANTIPROTOZOAL AGENTS; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION REGULATION; INTERFERON-GAMMA; INTERLEUKIN-10; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; LIPOPEPTIDES; LIVER; MACROPHAGES; MICE; MICE, INBRED C57BL; NITRIC OXIDE SYNTHASE TYPE II; RNA, MESSENGER; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 4;

EID: 84879444165     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.01468-12     Document Type: Article

References (78)

1. Murray HW. 2005. Prevention of relapse after chemotherapy in a chronic intracellular infection: mechanisms in experimental visceral leishmaniasis. J. Immunol. 174:4916-4923.
2. Murray HW. 2004. Progress in treatment of a neglected disease: visceral leishmaniasis. Expert Rev. Anti Infect. Ther. 2:279 -292.
3. Murray HW, Delph-Etienne S. 2000. Role of endogenous gamma interferon and macrophage microbicidal mechanisms in host response to chemotherapy in experimental visceral leishmaniasis. Infect. Immun. 68: 288-293.
4. Kaye PM, Svensson M, Ato M, Maroof A, Polley R, Stager S, Zubairi S, Engwerda CR. 2004. The immunopathology of experimental visceral leishmaniasis. Immunol. Rev. 201:239 -253.
5. Wilson ME, Jeronimo SMB, Pearson RD. 2005. Immunopathogenesis of infection with the visceralizing Leishmania species. Microb. Pathog. 38: 147-160.
6. Stanley AC, Engwerda CR. 2007. Balancing immunity and pathology in visceral leishmaniasis. Immunol. Cell Biol. 85:138 -147.
7. Amprey JL, Im JS, Turco SJ, Murray HW, Porcelli S, Spath GF. 2004. A subset of liver NK T cells is activated during Leishmania donovani infection by CD1d-bound lipophosphoglycan. J. Exp. Med. 200:895-904.
8. Stager S, Alexander J, Carter KC, Brombacher F, Kaye PM. 2003. Both interleukin-4 (IL-4) and IL-4 receptor a signaling contribute to the development of hepatic granulomas with optimal antileishmanial activity. Infect. Immun. 71:4804-4807.
9. McFarlane E, Carter KC, McKenzie AN, Kaye PM, Brombacher F, Alexander J. 2011. Endogenous IL-13 plays a crucial role in liver granuloma maturation during Leishmania donovani infection, independent of IL-4R
10. Murray HW. 2001. Tissue granuloma structure-function in experimental visceral leishmaniasis. Int. J. Exp. Pathol. 82:249 -267.
11. Beattie L, Peltan A, Maroof A, Kirby A, Brown N, Coles M, Smith DF, Kaye PM. 2010. Dynamic imaging of experimental Leishmania donovaniinduced hepatic granulomas detects Kupffer cell-restricted antigen pre-sentation to antigen-specific CD8 T cells. PLoS Pathog. 6(3):e1000805. doi:10.1371/journal.ppat.1000805.
12. Murray HW, Lu CM, Mauze S, Freeman S, Moreira AL, Kaplan G, Coffman RL. 2002. Interleukin-10 (IL-10) in experimental visceral leishmaniasis and IL-10 receptor blockade as immunotherapy. Infect. Immun. 70:6284-6293.
13. Rosas LE, Satoskar AA, Roth KM, Keiser TL, Barbi J, Hunter C, de Sauvage FJ, Satoskar AR. 2006. IL-12R (WSX-1/TCCR) gene-deficient mice display enhanced resistance to Leishmania donovani but develop severe liver immunopathology. Am. J. Pathol. 168:158 -166.
14. Murray HW, Flanders KC, Donaldson DD, Sypek JP, Gotwals PJ, Liu J, Ma X. 2005. Antagonizing deactivating cytokines to enhance host defense and chemotherapy in experimental visceral leishmaniasis. Infect. Immun. 73:3903-3911.
15. Murray HW. 2008. Accelerated control of visceral Leishmania donovani infection in interleukin-6-deficient mice. Infect. Immun. 76:4088-4091.
16. Murray HW, Nathan CF. 1999. Macrophage microbicidal mechanisms in vivo: reactive nitrogen vs. intermediates in the killing of intracellular visceral Leishmania donovani. J. Exp. Med. 189:741-746.
17. Alexander J, Carter KC, Al-Fasi N, Satoskar A, Brombacher F. 2000. Endogenous IL-4 is necessary for effective drug therapy against visceral leishmaniasis. Eur. J. Immunol. 30:2935-2943.
18. Murray HW, Xiang Z, Ma X. 2006. Responses to Leishmania donovani in mice deficient in both phagocyte oxidase and inducible nitric oxide synthase. Am. J. Trop. Med. Hyg. 74:1013-1015.
19. Tuon F, Amato V, Bacha H, Duarte M, Neto V. 2008. Toll-like receptors and leishmaniasis. Infect. Immun. 76:866-872.
20. Silvestre R, Santarem N, Tavares J, Silva AM, Cordeiro-da-Silva A. 2009. Recognition of Leishmania parasites by innate immunity. Immunol. Endocr. Metab. Agents Med. Chem. 9:106 -127.
21. Faria MS, Reis FCG, Lima APCA. 2012. Toll-like receptors in Leishmania infections: guardians or promoters? J. Parasitol. Res. 2012: Article ID 930257. doi:10.1155/2012/930257.
22. Singh RK, Srivastava A, Singh N. 2012. Toll-like receptor signaling: a perspective to develop vaccine against leishmaniasis. Microbiol. Res. 167: 445-451. doi:10.1016/j.micres.2012.01.002.
23. Paun A, Bankoti R, Joshi T, Potha PM, Stager S. 2011. Critical role of IRF-5 in the development of T helper 1 responses to Leishmania donovani infection. PLoS Pathog. 7(1):e1001246. doi:10.1371/journal.ppat .1001246.
24. Paul J, Karmakar S, De T. 2012. TLR mediated distinct IFN-γ/IL-10 pattern induces protective immunity against murine visceral leishmaniasis. Eur. J. Immunol. 42:2087-2099. doi:10.1002/eji.20124228.
25. Cezario GAG, de Oliviera LRC, Peresi E, Nicolete VC, Polettini J, de Lima CRG, Gatto M, Calvi SA. 2011. Analysis of the expression of toll-like receptors 2 and 4 and cytokine production during experimental Leishmania chagasi infection. Mem. Inst. Oswaldo Cruz 106:573-583.
26. Bhattacharya P, Bhattacharjee S, Gupta G, Majumder S, Adhikari A, Mukherjee A, Mujumdar SB, Saha B, Majumdar S. 2010. Arabinosylated lipoarabinomannan-mediated protection in visceral leishmaniasis through up-regulation of Toll-like receptor 2 signaling: an immunoprophylactic approach. J. Infect. Dis. 202:145-155.
27. Shakya N, Sane SA, Shankar S, Gupta S. 2011. Effect of Pam3Cys induced protection on the therapeutic efficacy of miltefosine against experimental visceral leishmaniasis. Peptides 32:2131-2133.
28. Karmakar S, Bhaumik SK, Paul J, De T. 2012. TLR4 and NKT cell synergy in immunotherapy against visceral leishmaniasis. PLoS Pathog. 8(4):e1002646. doi:10.1371/journal.ppat.1002646.
29. Datta N, Mukherjee S, Das L, Das PK. 2003. Targeting of immunostimulatory DNA cures experimental visceral leishmaniasis through nitric oxide upregulation and T cell activation. Eur. J. Immunol. 33:1508 -1518.
30. Tewary P, Mehta J, Sukumaran B, Madhubala R. 2004. Vaccination with Leishmania soluble antigen and immunostimulatory oligodeoxynucleotides induces specific immunity and protection against Leishmania donovani infection. FEMS Immunol. Med. Microbiol. 42:241-248.
31. Gupta S, Sane SA, Shakya N, Vishwakarma P, Haq W. 2011. CpG oligodeoxynucleotide 2006 and miltefosine, a potential combination for treatment of experimental visceral leishmaniasis. Antimicrob. Agents Chemother. 55:3461-3464.
32. Shi X, Liu L, Xiang Z, Mitsuhashi M, Wu R, Ma X. 2004. Gene expression analysis in interleukin-12-induced suppression of mouse mammary carcinoma. Int. J. Cancer 110:570 -578.
33. Raman VS, Bhatia A, Picone A, Whittle J, Bailor HR, O'Donnell J,Pattabhi S, Guderian JA, Mohamath R, Duthie MS, Reed SG. 2010. Applying TLR synergy in immunotherapy; implications in cutaneous leishmaniasis. J. Immunol. 185:1701-1710.
34. Oliveira-Nascimento L, Massari P, Wetzler LM. 12 April 2012. The role of TLR2 in infection and immunity. Front. Immunol. 3:79. [Epub ahead of print.] doi:10.3389/fimmu.2012.00079.
35. Netea MG, Van der Meer JWM, Sutmuller RP, Adema GJ, Kullberg B-J. 2005. From the Th1/Th2 paradigm towards a Toll-like receptor/T helper bias. Antimicrob. Agents Chemother. 49:3991-3996.
36. Yang H-Z, Cui B, Liu H-Z, Mi S, Yan J, Hua F, Lin H, Cai WF, Xie WJ, Lv XX, Wang XX, Xin BM, Zhan QM, Hu ZW. 2009. Blocking TLR2 activity attenuates pulmonary metastases of tumor. PLoS One 4(8):e6520. doi:10.1371/journal.pone.0006520.
37. Yang H-Z, Cui B, Liu H-Z, Chen Z-R, Yan H-M, Hua F, Hu Z-W. 2009. Targeting TLR2 attenuates pulmonary inflammation and fibrosis by reversion of suppressive immune microenvironment. J. Immunol. 182:692- 702.
38. Murray HW, Montelibano C, Peterson R, Sypek JP. 2000. Interleukin 12 regulates the response to chemotherapy in experimental visceral leishmaniasis J. Infect. Dis. 182:1497-1502.
39. Owens BMJ, Moore JWJ, Kaye PM. 2012. IRF7 regulates TLR2-mediated activation of splenic CD11chi dendritic cells. PLoS One 7(7):e41050. doi: 10.1371/journal.pone.0041050.
40. Netea MG, Van der Meer JWM, Kullberg B-J. 2004. Toll-like receptors as an escape mechanism from host defense. Trends Microbiol. 12:484- 488.
41. Shi Z, Cai Z, Sanchez A, Zhang T, Wen S, Wang J, Yang J, Fu S, Zhang D. 2011. A novel Toll-like receptor that recognizes vesicular stomatitis virus. J. Biol. Chem. 286:4517- 4524.
42. Engwerda CR, Murphy ML, Cotterell SE, Smelt SC, Kaye PM. 1998. Neutralization of IL-12 demonstrates the existence of discrete organspecific phases in the control of Leishmania donovani. Eur. J. Immunol. 28:669-680.
43. Satoskar AR, Rodig S, Telford SR, Satoskar AA, Ghosh SK, von Lichtenberg F, David JR. 2000. IL-12 gene-deficient C57BL/6 mice are susceptible to Leishmania donovani but have diminished hepatic pathology. Eur. J. Immunol. 30:834-839.
44. Murray HW, Jungbluth A, Ritter E, Montelibano C, Marino MW. 2000. Visceral leishmaniasis in mice devoid of tumor necrosis factor and response to treatment. Infect. Immun. 68:6289-6293.
45. Netea M, Sutmuller R, Hermann C, Van der Meer J, Hartung T, Adema G, Kullberg B. 2004. Toll-like receptor 2 suppresses immunity against Candida albicans through induction of IL-10 and regulatory T cells. J. Immunol. 172:3712-3718.
46. Kim HS, Go H, Akira S, Chung DH. 2011. TLR2-mediated protection of IL-27 and chemokines by respiratory epithelial cells promotes bleomycininduced pulmonary fibrosis in mice. J. Immunol. 187:4007- 4017.
47. Stager S, Maroof A, Zubairi S, Sanos SL, Kopf M, Kaye PM. 2006. Distinct roles for IL-6 and IL-12p40 in mediating protection against Leishmania donovani and the expansion of IL-10 CD4 T cells. Eur. J. Immunol. 36:1764 -1771.
48. Maroof A, Beattie L, Zubairi S, Svensson M, Stager S, Kaye PM. 2008. Posttranscriptional regulation of IL10 gene expression allows natural killer cells to express immunoregulatory function. Immunity 29:295-305.
49. Bhattacharyya S, Ghosh S, Jhonson PL, Bhattacharya SK, Malumdar S. 2001. Immunomodulatory role of interleukin-10 in visceral leishmaniasis: defective activation of protein kinase C-mediated signal transduction events. Infect. Immun. 69:1499 -1507.
50. Cheekatla SS, Aggarwal A, Nail S. 2012. mTOR signaling pathway regulates the IL-12/IL-10 axis in Leishmania donovani infection. Med. Microbiol. Immunol. 201:37- 46.
51. Mukherjee B, Mukhopadhyay R, Bannerjee B, Chowdhury S, Mukherjee S, Maskar K, Allam US, Chakravortty D, Sundar S, Dujardin Roy J-CS. 2013. Antimony-resistant but not antimony-sensitive Leishmania donovani up-regulates host IL-10 to overexpress multidrug-resistant protein 1. Proc. Natl. Acad. Sci. U. S. A. 110(7):E575-E582. doi:10.1073/pnas.1213839110.
52. Dillon S, Agrawal A, Van Dycke T, Landreth G, McCauley I, Koh A, Maliszewki C, Akira S, Pulendran B. 2004. Toll-like receptor 2 ligand stimulates Th2 responses in vivo, via induction of extracellular signalregulated kinase mitogen-activated protein kinase and c-Fos in dendritic cells. J. Immunol. 172:4733- 4743.
53. Yamazaki S, Okada K, Maruyama A, Matsumoto M, Yagita H, Seya T. 2011.TLR2-dependent induction of IL-10 and Foxp3 CD25 CD4 regulatory T cells prevents effective anti-tumor immunity induced by Pam2 lipopeptides in vivo. PLoS One 6(4):e18833. doi:10.1371/journal.pone.0018833.
54. Jayakumar A, Castillo TM, Park E, Goldsmith-Pestana K, Blackwell JM, McMahon-Pratt DD. 2011. TLR/2 activation during heterologous primeboost vaccination (DNA-MVA) enhances CD8 T cell responses providing protection against Leishmania (Viannia). PLoS Negl. Trop. Dis. 5(6): e1204. doi:10.1371/journal.pntd.0001204.
55. Meng G, Grabiec A, Rutz M, Metzger J, Luppa PB, Wagner H, Bauer S, Kirschning CJ. 2004. Murine TLR2 expression analysis and systemic antagonism by usage of specific monoclonal antibodies. Immunol. Lett. 98: 200-207.
56. Spiller S, Elson G, Dreher S, Mueller T, Freundenberg M, Daubeuf B, Wagner H, Kirschning CJ. 2008. TLR4-induced IFN-γ production increases TLR2 sensitivity and drives Gram-negative sepsis in mice. J. Exp. Med. 205:1747-1754.
57. Guerra CS, Silva RMM, Carvalho LOP, Calabrese KS, Bozza PT, Corte-Real S. 2010. Histopathological analysis of initial cellular response in TLR2-deficient mice experimentally infected by Leishmania (L.) amazonensis. Int. J. Exp. Pathol. 91:451- 459.
58. Kropf P, Freudenberg MA, Modolell M, Price HP, Herath S, Antoniazi S, Galanos C, Smith DF, Muller I. 2004. Toll-like receptor 4 contributes to efficient control of infection with the protozoan parasite Leishmania major. Infect. Immun. 72:1920 -1928.
59. Abou Fakher FH, Rachinel N, Klimczak M, Louis J, Doyen N. 2009. TLR9-dependent activation of dendritic cells by DNA from Leishmania major favors Th1 cell development and the resolution of lesions. J. Immunol. 182:1386 -1396.
60. Vargas-Inchaustegui DA, Tai W, Xin L, Hogg AE, Corry DB, Soong L. 2009. Distinct roles for MyD88 and Toll-like receptor 2 during Leishmania braziliensis infection in mice. Infect. Immun. 77:2948 -2956.
61. Van Maren WWC, Nierkens S, Toonen LW, Bolscher JM, Sutmuller RPM, Adema GJ. 2011. Multifaceted effects of synthetic TLR2 ligand and Legionella pneumophilia on Treg-mediated suppression of T cell activation. BMC Immunol. 12:23. doi:10.1186/1471-2172-12-23.
62. Zhang Y, Luo F, Cui Y, Liu N, Wang L, Xu D, Chu Y. 2011. TLR1/TLR2 agonist induces tumor regression by reciprocal modulation of effector and regulatory T cells. J. Immunol. 186:1963-1969.
63. Chen Q, Davidson TS, Hutter EN, Shevach EM. 2009. Engagement of TLR2 does not reverse the suppressor function of mouse regulatory T cells, but promotes their survival. J. Immunol. 183:4458-4466.
64. Re F, Strominger JL. 2001. Toll-like receptor 2 (TLR2) and TLR4 differentially activate human dendritic cells. J. Biol. Chem. 276:37692-37699.
65. Agrawal S, Agrawal A, Doughty B, Gerwitz A, Van Dyke T, Pulendran R. 2003. Cutting edge: different toll-like receptor agonists instruct dendritic cells to induce distinct Th responses via differential modulation of extracellular signal-regulated kinase-mitogen-activated protein kinases and c-fos. J. Immunol. 171:4984-4988.
66. Dillon S, Agrawal S, Banerjee K, Letterio J, Denning TL, Oswald-Richter K, Kasprowicz DJ, Kellar K, Pare J, van Dyke T, Ziegler S, Unutmaz D, Pulendran B. 2006. Yeast zymosan, a stimulus for TLR2 and dectin-1, induces regulatory antigen-presenting cells and immunological tolerance. J. Clin. Invest. 116:916 -928.
67. Arko-Mensah J, Julian E, Singh M, Fernandez C. 2007. TLR2 but not TLR4 signaling is critically involved in the inhibition of IFN-γ-induced killing of mycobacteria by murine macrophages. Scand. J. Immunol. 65: 148-157.
68. Pecora ND, Gehring AJ, Canaday DH, Boom WH, Harding CV. 2006. Mycobacterium tuberculosis LprA is a lipoprotein agonist of TLR2 that regulates innate immunity and APC function. J. Immunol. 177:422- 429.
69. Banaiee N, Kincaid EZ, Buchwald U, Jacobs WR, Ernst JD. 2006. Potent inhibition of macrophage responses to IFN-γ by live virulent Mycobacterium tuberculosis is independent of mature mycobacterial lipoproteins but dependent on TLR2. J. Immunol. 176:3019 -3027.
70. Jang S, Uematsu S, Akira S, Salgame P. 2004. IL-6 and IL-10 induction from dendritic cells in response to Mycobacterium tuberculosis is predominantly dependent on TLR2-mediated recognition. J. Immunol. 173: 3392-3397.
71. Yanagawa Y, Onoe K. 2007. Enhanced IL-10 production by TLR4- and TLR2 primed dendritic cells upon TLR restimulation. J. Immunol. 178: 6173-6180.
72. Mosser DM, Miles SA. 2007. Avoidance of innate immune mechanisms by the protozoan parasite, Leishmania spp., p 118 -129. In Denkers E, Gazzinelli R (ed), Protozoans in macrophages. Landes Bioscience, Austin, TX.
73. Srivastava A, Singh N, Mishra M, Kumar V, Gour JK, Bajpai S, Singh S, Pandey HP, Singh RK. 2012. Identification of TLR inducing Th1-responsive Leishmania donovani amastigote-specific antigens. Mol. Cell. Biochem. 359:359 -368. doi:10.1007/s11010-011-1029-5.
74. Re F, Strominger JL. 2004. IL-10 released by concomitant TLR2 stimulation blocks the induction of a subset of Th1 cytokines that are specifically induced by TLR4 or TLR3 in human dendritic cells. J. Immunol. 173: 7548-7555.
75. Ansari NA, Kumar R, Gautam S, Nylén S, Singh OP, Sundar S, Sacks D. 2011. IL-27 and IL-21 are associated with T cell IL-10 responses in human visceral leishmaniasis. J. Immunol. 186:3977-3985.
76. Saraiva M, O'Garra A. 2010. The regulation of IL-10 production by immune cells. Nat. Rev. Immunol. 10:170 -181.
77. McConville MJ, Blackwell JM. 1991. Developmental changes in the glycosylated phosphatidylinositols of Leishmania donovani. J. Biol. Chem. 266:15170 -15179.
78. Drage MG, Pecora ND, Hise AG, Febbraio M, Silverstein RL, Golenbock DT, Boom WH, Harding CV. 2009. TLR2 and its co-receptors determine responses of macrophages and dendritic cells to lipoproteins of Mycobacterium tuberculosis. Cell. Immunol. 258:29 -37.